The decision was taken at the meeting of the Board of Directors held on January 23, 2026. Cipla informed stock exchanges that the approval has been granted in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also stated that the detailed information required under the SEBI Listing Regulations read with the SEBI Master Circular dated November 11, 2024, has been provided as part of the disclosure.
P R Ramesh has been associated with Cipla as an Independent Director since July 1, 2021 and currently serves as the Chairman of the company’s Audit Committee. His reappointment is subject to approval by the shareholders of the company.
Ramesh is a Commerce graduate from Osmania University, Hyderabad, and is a Fellow Member of the Institute of Chartered Accountants of India (ICAI). He retired on March 31, 2020, as Director of Deloitte & Touche Assurance & Enterprise Risk Services India Private Limited. During his professional career spanning over 45 years, he has also served as a member of the Deloitte Global Board and Deloitte Asia Pacific Board.
His professional experience spans across multiple sectors including manufacturing, banking and financial services, technology, media, telecommunications, energy and resources, and consumer business. In addition to his role at Cipla, Ramesh serves on the boards of several leading companies such as Air India, Larsen & Toubro (L&T), Nestlé India, Crompton Greaves Consumer Electricals, and ITC Hotels.
Cipla clarified that there is no relationship between P R Ramesh and any other directors of the company. The company further confirmed that Ramesh is not debarred from holding the office of director by virtue of any SEBI order or by any other statutory authority.
According to Cipla Limited, the reappointment reflects the company’s continued focus on strong corporate governance and experienced board leadership.
Also Read: Cipla Emerges as Domestic Contender in Anti-Obesity Market with Yurpeak
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.